Drug
Ecallantide clinical trials
Also written DX-88.
- studies test it
- 10
- open now
- 0
- in phase 3
- 4
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
10 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 6
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Shire (6) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Fovea Pharmaceuticals SA (1)
Studies
Open first, then newest update. How each study uses ecallantide is read from its arms, and is right about nine times in ten.
Testing it · 10
- Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00262080Written as ecallantide
- Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced AngioedemaTerminatedPhase 2ShireNCT01343823Written as ecallantide 60 mg
- Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00456508Written as ecallantide
- Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00457015Written as ecallantide
- EDEMA2: Evaluation of DX-88's Effect in Mitigating AngioedemaCompletedPhase 2ShireNCT01826916Written as DX-88 (ecallantide)
- Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary AngioedemaWithdrawnPhase 2/3ShireNCT01253382Written as ecallantide
- Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/ReplacementTerminatedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00448864Written as Ecallantide
- A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss VolumeCompletedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00816023Written as ecallantide
- Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac SurgeryCompletedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00888940Written as Ecallantide
- Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein OcclusionTerminatedPhase 1Fovea Pharmaceuticals SANCT00969293Written as FOV2302 (Ecallantide)
Codes
What other systems call ecallantide · ClinicalTrials.gg INT004925
- MeSH (NLM) C511194ecallantideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5Q6TZN2HNMECALLANTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 658708Confirmed FDA, Wikidata
- Wikidata Q1280166ecallantideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65505EcallantideConfirmed FDA, Wikidata
- DrugBank DB05311One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C511194 | ecallantide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5Q6TZN2HNM | ECALLANTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 658708 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1280166 | ecallantide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65505 | Ecallantide | Confirmed FDA, Wikidata |
| DrugBank | DB05311 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.